1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Mezzion Pharma Co.,Ltd.

Mezzion Pharma Co.,Ltd.

140410.KQ
Mezzion Pharma Co.,Ltd.KR flagKOSDAQ
56,600.00
KRW
+1,900.00
- -
1.72TMarket Cap
Mezzion Pharma Co.,Ltd.
140410.KQ
(KOSDAQ)

Recent

price

56,600.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,343.19
279.34
378.33
201.37
212.49
659.85
395.84
250.23
766.14
689.8
1,100.84
998.74
1,149.55
1,123.96
288.72
262.68
264.08
Revenue per Share
905.67
176.67
105
-38
-112.33
186.67
-587.33
-666.67
-757.67
-895
-531.67
-509.7
-1,358
-451
-653
-1,160
-1,223.31
Basic EPS, GAAP
934.12
-101.45
130.84
-162.99
-207.96
53.41
-282.53
-683.71
-894.93
-846
-589.48
-796.4
-517.63
-810.75
-1,071.81
-991.69
-1,023.13
Free Cash Flow per Basic Share
- -
- -
- -
8.34
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1,064.28
1,248.71
1,133.11
1,122.61
957.4
1,146.55
632.55
-42.72
-795.17
-1,655.81
-2,180.6
-2,635.63
-3,654.53
-3,859.3
-4,297.06
-5,411.52
-5,574.05
Book Value per Share
1,367.68
1,499.22
2,741.06
2,794.53
2,761.44
2,652.65
2,374.84
2,308.6
2,235.07
1,586.29
1,867.2
1,821.64
921.11
1,718.52
590.85
-1,060.18
-1,390.43
Tangible Book Value per Share
18
18
23
22
23
23
22
22
25
26
26
27
27
28
30
30
30
Basic Weighted Avg Shares
24,379
5,067
8,592
4,402
4,857
14,926
8,751
5,586
19,088
17,920
28,634
26,654
30,726
31,721
8,612
7,910
7,972
Sales/Revenue/Turnover
71.85
55.82
19.56
-56.17
-101.22
-18.31
-82.5
-301.59
-114.87
-136.62
-26.3
-63.02
-75.93
-45.68
-166.05
-212
-174.68
Operating Margin (%)
55
40
49
48
151
343
415
62
228
1,332
1,432
1,586
1,658
1,546
958
988
920
Depreciation Expense
16,438
3,204
2,385
-831
-2,568
4,223
-12,985
-14,882
-18,876
-23,251
-13,829
-13,603
-36,298
-12,728
-19,477
-34,929
-36,928
Net Income, GAAP
15.04
21.69
20.49
- -
- -
18.19
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
67.43
63.24
27.75
-18.87
-52.86
28.29
-148.38
-266.42
-98.89
-129.75
-48.3
-51.03
-118.13
-40.13
-226.17
-441.61
-463.23
Profit Margin (%)
16,330
16,831
56,626
58,103
62,804
83,609
77,713
50,007
52,278
38,339
45,155
45,678
19,817
44,628
15,255
-33,987
-43,953
Working Capital
- -
- -
- -
- -
- -
25,236
26,255
- -
- -
2,420
3,104
2,338
1,625
1,005
921
1,151
1,032
LT Debt
24,824
28,170
63,336
62,177
66,151
62,537
52,809
53,169
57,319
42,830
56,810
62,793
26,240
61,444
46,063
17,195
15,511
Total Equity
81.7
7.99
2.92
- -
- -
-2.91
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
148.12
15.27
9.86
- -
- -
14.78
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
148.12
15.27
9.86
-3.3
-11.06
17.66
-65.05
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
9,996
10,722
11,388
LT Borrowings
- -
- -
- -
LT Finance Leases
930
1,151
1,032
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
1,952,125
2,705,946
2,614,175

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
43,508
45,586
38,313
Cash, Cash Equivalents & STI
28,493
25,574
17,419
Accounts Receivable, Net
1,104
1,078
939
Inventories
5,379
5,302
5,242
Total Current Liabilities
49,394
79,572
82,267
Payables & Accruals
- -
- -
- -
ST Debt
9,996
10,722
11,388
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.09%
-0.24%
-62.67%
Free Cash Flow
-35.6%
20.44%
-6.59%
Net Income, GAAP
-15.08%
46.53%
79.34%
Sales/Revenue/Turnover
14.85%
-13.88%
-8.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,158
2,269
2,261
1,924
8,612
2025
1,953
1,744
2,128
2,084
7,910
2026
2,015
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.45
-55
-213
- -
-653
2025
-110
- -
-171.05
- -
-1,160
2026
-174.66
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
LifeMD, Inc. (LFMD)
NIHON CHOUZAI Co.,Ltd. (3341.T)
Pharmaron Beijing Co., Ltd. (300759.SZ)
Medexus Pharmaceuticals Inc. (MDP.TO)
ABL Bio Inc. (298380.KQ)
Damora Therapeutics, Inc. (GLTO)
Business
Mezzion Pharma Co., Ltd. develops, manufactures, and sells pharmaceutical products with a focus on treatments for rare and underserved diseases, including udenafil (JURVIGO) in phase 3 clinical trials for improving exercise capacity and physiology in Fontan patients aged 12 years and older; udenafil for erectile dysfunction (Zydena), benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, overactive bladder, and chronic obstructive pulmonary disease; and exploratory applications in autosomal dominant polycystic kidney disease. The company operates primarily in South Korea with global clinical development led by its U.S. subsidiary, Mezzion Pharmaceuticals, Inc., headquartered in Fort Lee, New Jersey, and targets patients with congenital heart conditions, vascular diseases, and renal disorders through licensing agreements with partners such as Warner in the U.S., Valenta in Russia, Nycomed in Mexico, and Dr. Falk in Europe. Founded in 2002 and headquartered in Seoul, South Korea, the company changed its name from Dong-A Pharmtech Co., Ltd. in April 2013. In June 2025, Mezzion secures approximately $20 million in strategic funding from Midas-Meritz New Technology Finance Association and KDBC-Korea Investment & Securities New Technology Investment Association to advance the global phase 3 FUEL-2 trial of udenafil for Fontan patients; expands its udenafil pipeline with a pre-clinical study for ADPKD in collaboration with Mayo Clinic; and benefits from new ICD-10 codes recognizing Fontan-associated conditions to support regulatory and coverage advancements.